THE COMPETITIVENESS OF Oraticx PROBIOTICS
FOR ORAL HEALTH & TECHNOLOGY

[Adhesive Properties]
According to the results of the clinical trial, which compared probiotics’ adhesive properties, active oraCMU® was still
observed on the surface of oral cavity of 84% of participants, who stopped taking oraCMU® 4 weeks ago.
[Suppression of Bad-Smelling Compounds]
oraCMU® was proved to be the most effective in suppressing VSC and bad breath compared With 4 other probiotic strains.
[Coaggregation with Bacteria Which Cause Oral Diseases]
A comparative study of coaggregation of probiotics with bacteria, which cause oral diseases, found that oraCMU® more
effectively disrupts bacterial activities leading to halitosis and periodontitis and prevents oral diseases than all other
probiotic strains concerned.
[Antibacterial Activities against Bacteria That Cause Halitosis or Periodontitis]
A comparative study of antibacterial activities of probiotics found that oraCMU® is more effective to inhibit growth in
bacteria which cause halitosis and periodontitis than all other probiotic strains concerned.
our patented probiotics

oraCMU® (Weissella cibaria CMU) and oraCMS1® (Weissella cibaria CMS1) are our patented probiotics. Both probiotic strains that promote oral health were isolated from the saliva of 460 kids, who had healthy mouth.

[Low Caries Risk]

A comparative study of PAV of probiotic strains in carbohydrates found that oraCMU® is the least likely to influence the development of dental caries.

[Significant Reduction in Plaque]

The clinical trial to investigate the efficacy of probiotic strains in preventing dental caries discovered that oraCMU® has greater inhibitory effects on plaque formation than probiotic strains provided by other companies.

[Inhibition of Plaque Formation by S. Mutans]

A comparative study of probiotic strains’ inhibitory effects on plaque formation by bacteria(S. mutans) that cause dental caries discovered that oraCMU® inhibits plaque formation most efficiently.

A Combination of Mechanisms of Action

1. Coaggregation of the probiotics

Coaggregation of the probiotics with pathogenic bacteria enables the probiotics to block the adherence of pathogenic bacteria to epithelial cells and teeht and contribute to the elimination of pathogenic bacteria.

2. Suppression of biofilm generation

Bacteria that cause dental caries metabolize produce sticky substances, which contribute to plaque formation. Inhibit such bacterial activities in the oral cavity, thereby blocking biofilm (tartar or dental plaque) formation.

3. Secretion of 4 antimicrobial substances

Secretes antimicrobial substances such as organic acids, hydrogen peroxide, fatty acids, and bacteriocin outsice of cells, thereby inhibiting the growth of bacteria which cause halitosis and periodontitis.

4. Competition with pathogens for binding sites on epithelial cells

Block th adherence of pathogens, which cause halitosis or periodontitis, to epithelial cells, thereby preventing various orla diseases.

5. IInhibition of enzyme activity and gene expression related to VSC production

Inhibit mgl gene expression in P.gingivalis, the bacteria which produce VSC, the main cause of bad breah.
The probiotics also inhibigt and block METase activities.

6. The inhibition of formation of substances that promote cellular inflammation

Inhibit the production of substances (NO, IL-1B, and IL-6, all of which promote inflammation) induced by general probiotics for oral health.

Probiotics for Oral Health
1 U.S. Patent & 4 Korea Patents

Our patented probiotics. Offer a fundamental solution to various oral health problems. Help to restore the balance of your oral microbiome.

Brand history

The Beginning of Research
on Probiotics for Oral Health kickstarted by Dr. Jong-Suk Oh

1997

Successfully Isolated 4 Probiotic Strains: CMU, CMS1, CMS2, CMS of the 1,640 strains derived from the saliva of children with healthy oral cavity, OraPharm isolated 4 strains (oraCMU®, oraCMS1®, oraCMS2®, oraCMS3®) that have excellent functions in safety, oral colonization, and control of harmful bacteria

2004

Obtained Multiple Patenta
We have obtained multiple patents and certificates related to probiotics since 2006.

2006

OraPharm was established in 2014 as a company specialized in probiotics for oral health. Dr. Mi-Sun Kang who is the core members of the research team led by Dr. Oh became a chief of R&D and has been doing various researches on the oral cavity ever since.

2014

Weissella cibaria is recognized as a food ingredient
by the Ministry of Food and Drug Safety (MFDS).

2016

Certificate of New Excellent Technology is issued by Ministry of Health and Welfare (MOUW) to the company

2017

Obtained Patent of Composition for preventing or improving cavities containing Weisella ciberia strains
Kick-started Antivirus Study with probiotics

2018-2020

"Pet Biome" which is Probiotics for Pet Launched
Started exporting Orapharm Green Breath and Oradenti to Australia
Orapharm USA established in Irvine, California
MOU with Chosun University on development of probiotics for Prevention of dementia

2021

Global brand "OraTicx" newly launched
Probiotics for Kids " OraTicx Kids" launched
MOU with CJ Wellcare on development of probiotics
2022 Korea Prestige Brand Award

2022